ViaLase, Inc., a clinical-stage medical technology company specializing in innovative glaucoma treatments, has announced its participation in the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, scheduled for April 5-8, 2024, in Boston, Massachusetts. The company will showcase clinical data and provide insights into its business and technology at booth #2417 during the event.
At the ASCRS 2024 meeting, ViaLase will present findings on the ViaLase Laser* and share outcomes from the first-in-human study of femtosecond laser image-guided high-precision trabeculotomy (FLigHT) treatment for glaucoma patients. The company recently completed a Series C financing round to support ongoing clinical, regulatory, and commercial efforts for the ViaLase Laser.
Dr. Tibor Juhasz, Founder and CEO of ViaLase, expressed enthusiasm about presenting the latest clinical data at ASCRS, emphasizing the potential of ViaLase technology to revolutionize glaucoma treatment. The ViaLase Laser, incorporating femtosecond laser and high-definition imaging, offers a promising non-invasive option for early intervention in primary open-angle glaucoma.
Glaucoma, affecting approximately 76 million people worldwide, is a leading cause of irreversible blindness. Early detection and treatment are crucial to prevent vision loss caused by optic nerve deterioration. ViaLase aims to transform the glaucoma treatment landscape by providing innovative solutions to enhance patient care.
Based in Aliso Viejo, California, ViaLase is committed to leveraging its expertise in femtosecond laser technology to develop groundbreaking treatments for glaucoma patients. The company collaborates closely with healthcare providers, payers, societies, and patients to advance its mission of improving glaucoma care globally.
